Aegerion Pharmaceuticals Inc. plans a January launch of its homozygous familial hypercholesterolemia drug Juxtapid (lomitapide) with a target population that appears to be broader than FDA expectations.
The total adjustable market for the drug could be as many as 3,000, CEO Marc Beers said during a Dec. 24 conference call. FDA, in announcing approval of Juxtapid, said...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?